StocksCellectis SACLLS

CLLS

Cellectis SA

3.95 0.19 (5.05%)
Delayed Prices By NASDAQ, in USD Market Closed
Trade
S
3.94
B
3.99

Overview

Prev Close3.95
Day's Range 3.71 - 3.98
52 Week Range 2.85 - 16.49
Average Volume (3m)223.55K
1-Year Return-75.76%
Beta1.3588
Market Cap180.99M
P/E Ratio
Revenue33.39M
EPS-2.952
Dividend (Yield) (0%)
1 Day 1 Week 1 Month 3 Months 6 Months 1 Year 3 Years Max
Created with Highcharts 4.2.7 /Highstock 4.2.715/12/202128/02/202210/05/20223.004.005.006.007.008.009.0010.00
Chart times in UTC
Industry Pharmaceuticals Major
CEO André Choulika, PhD
Employees 294

FINANCIAL SUMMARY

For the quarter ended 31/3/2022, Cellectis SA's revenues decreased by 86.10% and amounted to 1.70M. Net income decreased by 23.78% to -34.76M. Net assets decreased by 14.13% to 203.05M and EPS decreased from -0.55 to -0.70.
CLLS's Investor Relations
Income StatementBalance SheetCash Flow Statement
Quarterly
Gross Margin
3.63%
Net Profit Margin
-398.74%
Operating Margin
-471.62%
Return On Investment
-28.63%
06/21
09/21
12/21
03/22
Total Revenue
11.16M
8.31M
12.21M
1.7M
Gross Profit
-577.28K
-901K
6.6M
-3.91M
Operating Income
-41.02M
N/A
-32.38M
-37.45M
Net Income
-41.56M
-40.07M
-28.08M
-34.76M